Conclusion: GLP-1based therapies are associated with predictable GI adverse effects, most of which are mild to moderate and manageable
Yes, injection site selection does matter when administering glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), or liraglutide (Victoza, Saxenda)
Although genetic factors are certainly at play, nature (genes) vs nurture (environment) still holds true, and our food system has changed
Early recommendations emphasized routine discontinuation of GLP-1 receptor agonists before elective procedures as a precautionary measure
A once-weekly formulation was later approved for diabetes in 2012
If the medication brings out pattern thinning (androgenetic alopecia), that can be progressive, but its treatable with standard hair growth therapies, Friedman says